Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans

Leiden University Medical Center (LUMC)

Status

Completed

Conditions

Insulin Resistance

Dyslipidemia

Treatments

Drug: Haloperidol

Study type

Interventional

Funder types

Other

Identifiers

NCT00625014

P05.009

Details and patient eligibility

About

We hypothesized that short-term treatment with haloperidol induces insulin resistance through a mechanistic route that is independent of weight gain. We therefore treated healthy non-obese men with haloperidol for 8 days, and studied the impact of these intervention on glucose and lipid metabolism by hyperinsulinemic euglycemic clamp, isotope dilution technology and indirect calorimetry.

Enrollment

8 patients

Sex

Male

Ages

20 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy men
20 kg/m2 < BMI < 26 kg/m2
Age 20-40 years
FPG < 6 mmol/L

Exclusion criteria

FPG > 6 mmol/L
BMI > 26 kg/m2
Psychiatric disorders and/or use of antipsychotic or antidepressants drugs at present or in the past.
A positive family history of schizophrenia
Any significant chronic disease
Renal, hepatic or endocrine disease
Use of medication known to influence lipolysis and/or glucose metabolism
Total cholesterol > 7mmol/L and/or triglycerides > 2 mmol/L
Recent weight changes or attempts to loose weight (> 3 kg weight gain or loss, within the last 3 months)
Difficulties to insert an intravenous catheter
Smoking (current)
Severe claustrophobia (ventilated hood)
Recent blood donation (within the last 2 months)
Recent participation in other research projects (within the last 3 months), participation in 2 or more projects in one year
Extensive sporting activities (more than 10 hours of exercise per week)